公开(公告)号：EP1554272B1

公开(公告)日：2006-10-25

申请号：EP03784749.8

申请日：2003-07-31

申请人： ELI LILLY AND COMPANY

发明人： BONJOUKLIAN, Rosanne ,  DE DIEGO GOMEZ, Jose, Eugenio Lilly, S. A. ,  DE DIOS, Alfonso Lilly, S. A. ,  HAMDOUCHI, Chafiq, Hamdouchi ,  LI, Tiechao ,  LOPEZ DE URALDE GARMENDIA, Beatriz Lilly, S. A. ,  VIETH, Michal ,  YORK, Jeremy, Schulenburg ,  DALLY, Robert, Dean ,  DEL PRADO CATALINA, Miriam, Filadelfa Lilly, S. A. ,  JARAMILLO, Carlos Lilly, S. A. ,  MARTIN CABREJAS, Luisa, Maria Lilly, S. A. ,  MONTERO SALGADO, Carlos Lilly, S. A. ,  PLEITE, Sheila Lilly, S. A. ,  SANCHEZ-MARTINEZ, Concepcion Lilly, S. A. ,  SHEPHERD, Timothy, Alan ,  WIKEL, James, Howard

IPC分类号： C07D409/14 ,  C07D403/04 ,  C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D409/04 ,  C07D417/04 ,  A61K31/41 ,  A61P35/04

CPC分类号： C07D403/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D513/04

摘要： The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.